Journal of NeuroVirology

, Volume 19, Issue 3, pp 228–238 | Cite as

Neurovirulence of Cryptococcus neoformans determined by time course of capsule accumulation and total volume of capsule in the brain

  • A. Pool
  • L. Lowder
  • Y. Wu
  • K. Forrester
  • J. Rumbaugh
Article
First Online:
Received:
Accepted:

Abstract

Cryptococcal meningitis remains a significant opportunistic infection in HIV-infected individuals worldwide, despite availability of antiretroviral therapies in developed nations. Current therapy with amphotericin B is difficult to administer and only partially effective. Mechanisms of cryptococcal neuropathogenesis are still not clearly defined. In the present study, we used a C57Bl/6 mouse model with intravenous inoculation of three isogenic strains of Cryptococcus neoformans: H99, Cap59, and Pkr1-33. These strains differ in their capsule production and are normocapsular, hypocapsular, and hypercapsular, respectively. We studied the role of capsule in the morbidity and mortality of our host animal. Surprisingly, we found that the hypercapsular strain was least virulent while the strains that produced less capsule were more virulent and had higher concentrations of organism in the brain. These results suggest that neurovirulence is related to total capsule volume and rate of capsule accumulation in the brain, rather than the amount of capsule produced per organism. Therapies which decrease central nervous system dissemination and inhibit replication rates in the brain may be more effective than therapies which target capsule production.

Keywords

Fungal meningitis Human immunodeficiency virus Hydrocephalus Intracranial pressure Opportunistic infection 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This research was funded by the Emory Center for AIDS Research (grant #P30 AI050409) to JAR. The authors report no other disclosures. Special thanks to Dr. William De l’Aune for his statistical expertise and support of this project.

References

  1. Bahn Y, Kojima K, Cox G, Heitman J (2005) Specialization of the HOG pathway and its impact on differentiation and virulence of Cryptococcus neoformans. Mol Biol Cell 16:2285–2300PubMedCrossRefGoogle Scholar
  2. Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, Bekker LG, Harrison T (2007) Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 45(1):76–80PubMedCrossRefGoogle Scholar
  3. Bicanic T, Wood R, Meintjes G, Rebe K, Brouwer A, Loyse A, Bekker LG, Jaffar S, Harrison T (2008) High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 47(1):123–130PubMedCrossRefGoogle Scholar
  4. Byrnes E 3rd, Li W, Ren P, Lewit Y, Voelz K, Fraser J, Dietrich F, May R, Chaturvedi S, Chaturvedi V, Heitman J (2011) A diverse population of Cryptococcus gattii molecular type VGIII in Southern Californian HIV/AIDS patients. PLoS Pathog 7(9):e1002205PubMedCrossRefGoogle Scholar
  5. Carroll S, Lafferty E, Flaczyk A, Fujiwara T, Homer R, Morgan K, Loredo-Osti J, Qureshi S (2012) Susceptibility to progressive Cryptococcus neoformans pulmonary infection is regulated by loci on mouse chromosomes 1 and 9. Infect Immun 80(12):4167–4176PubMedCrossRefGoogle Scholar
  6. CDC (2012) Cryptococcosis statistics. In: C. neoformans cryptococcosis. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/fungal/cryptococcosis-neoformans/statistics.html. Accessed 28 Feb 2013
  7. Chang Y, Kwon-Chung K (1994) Complementation of a capsule deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol 14:4912–4919PubMedGoogle Scholar
  8. Charlier C, Nielsen K, Daou S, Brigitte M, Chretien F, Dromer F (2009) Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect Immun 77(1):120–127PubMedCrossRefGoogle Scholar
  9. Chen G, McNamara D, Hernandez Y, Huffnagle G, Toews G, Olszewski M (2008) Inheritance of immune polarization patterns is linked to resistance versus susceptibility to Cryptococcus neoformans in a mouse model. Infect Immun 76(6):2379–2391PubMedCrossRefGoogle Scholar
  10. Chen S, Wright L, Golding J, Sorrell T (2000) Purification and characterisation of secretory phospholipase B, lysophospholipase and lysophospholipase transacylase from a virulent strain of the pathogenic fungus Cryptococcus neoformans. Biochem J 347(pt 2):431–439PubMedCrossRefGoogle Scholar
  11. Chen S, Muller M, Zhou J, Wright L, Sorrell T (1997) Phospholipase activity in Cryptococcus neoformans: a new virulence factor? J Infect Dis 175(2):414–420PubMedCrossRefGoogle Scholar
  12. Chrisman C, Albuquerque P, Guimaraes A, Nieves E, Casadevall A (2011) Phospholipids trigger Cryptococcus neoformans capsular enlargement during interactions with amoebae and macrophages. PLoS Pathog 7(5):e1002047PubMedCrossRefGoogle Scholar
  13. Chrisman C, Alvarez M, Casadevall A (2010) Phagocytosis of Cryptococcus neoformans by, and nonlytic exocytosis from, Acanthamoeba castellanii. Appl Environ Microbiol 76(18):6056–6062PubMedCrossRefGoogle Scholar
  14. Devi S, Schneerson R, Egan W, Ulrich T, Bryla D, Robbins J, Bennett J (1991) Cryptococcus neoformans serotype A glucuronoxylomannan–protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun 59(10):3700–3707PubMedGoogle Scholar
  15. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O (2007) Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 4(2):e21PubMedCrossRefGoogle Scholar
  16. D’Souza C, Alspaugh J, Yue C, Harashima T, Cox G, Perfect J, Heitman J (2001) Cyclic AMP-dependent protein kinase controls virulence of the fungal pathogen Cryptococcus neoformans. Mol Cell Biol 21(9):3179–3191PubMedCrossRefGoogle Scholar
  17. Fabrizio C, Carbonara S, Angarano G (2012) Cryptococcal meningitis. In: Wireko-Brobby G (ed) Meningitis. InTech, Rijeka, pp 135–144Google Scholar
  18. Farhi F, Bulmer G, Tacker J (1970) Cryptococcus neoformans. IV. The not-so-encapsulated yeast. Infect Immun 1:526–531PubMedGoogle Scholar
  19. Feldmesser M, Kress Y, Casadevall A (2001) Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology 147:2355–2365PubMedGoogle Scholar
  20. Frases S, Pontes B, Nimrichter L, Viana N, Rodrigues M, Casadevall A (2009) Capsule of Cryptococcus neoformans grows by enlargement of polysaccharide molecules. PNAS 106(4):1228–1233PubMedCrossRefGoogle Scholar
  21. Garcia-Hermoso D, Dromer F, Janbon G (2004) Cryptococcus neoformans capsule structure evolution in vitro and during murine infection. Infect Immun 72(6):3359–3365PubMedCrossRefGoogle Scholar
  22. Garcia-Rivera J, Chang Y, Kwon-Chung K, Casadevall A (2004) Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan. Eukaryot Cell 3:385–392PubMedCrossRefGoogle Scholar
  23. Goldman D, Fries B, Franzot S, Montella L, Casadevall A (1998) Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents. Proc Natl Acad Sci U S A 95(25):14967–14972PubMedCrossRefGoogle Scholar
  24. Granger D, Perfect J, Durack D (1985) Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J Clin Invest 76:508–516PubMedCrossRefGoogle Scholar
  25. Guerrero A, Jain N, Goldman D, Fries B (2006) Phenotypic switching in Cryptococcus neoformans. Microbiology 152:3–9PubMedCrossRefGoogle Scholar
  26. Guillot L, Carroll S, Homer R, Qureshi S (2008) Enhanced innate immune responsiveness to pulmonary Cryptococcus neoformans infection is associated with resistance to progressive infection. Infect Immun 76(10):4745–4756PubMedCrossRefGoogle Scholar
  27. Guimaraes A, Frases S, Cordero R, Nimrichter L, Casadevall A, Nosanchuk J (2010) Cryptococcus neoformans responds to mannitol by increasing capsule size in vitro and in vivo. Cell Microbiol 12:740–753PubMedCrossRefGoogle Scholar
  28. Hoag K, Lipscomb M, Izzo A, Street N (1997) IL-12 and IFN-gamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice. Am J Respir Cell Mol Biol 17(6):733–739PubMedCrossRefGoogle Scholar
  29. Hu G, Steen B, Lian T, Sham A, Tam N, Tangen K, Kronstad J (2007) Transcriptional regulation by protein kinase A in Cryptococcus neoformans. PLoS Pathog 3(3):e42PubMedCrossRefGoogle Scholar
  30. Huffnagle G, Boyd M, Street N, Lipscomb M (1998) IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J Immunol 160:2393–2400PubMedGoogle Scholar
  31. Hutson C, Abel J, Carroll D, Olson V, Braden Z, Hughes C, Dillon M, Hopkins C, Karem K, Damon I, Osorio J (2009) Comparison of West African and Congo Basin monkeypox viruses in BALB/c and C57BL/6 mice. PLoS One 5(1):e8912CrossRefGoogle Scholar
  32. Jung W, Sham A, White R, Kronstad J (2006) Iron regulation of the major virulence factors in the AIDS-associated pathogen Cryptococcus neoformans. PLoS Biol 4:e410PubMedCrossRefGoogle Scholar
  33. Kozel T, Gotschlich E (1982) The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J Immunol 129:1675–1680PubMedGoogle Scholar
  34. Kozel T, Pfrommer G, Guerlain A, Highison B, Highison G (1988) Strain variation in phagocytosis of Cryptococcus neoformans: dissociation of susceptibility to phagocytosis from activation and binding of opsonic fragments of C3. Infect Immun 56:2794–2800PubMedGoogle Scholar
  35. Kwon-Chung K, Rhodes J (1986) Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect Immun 51(1):218–223PubMedGoogle Scholar
  36. Levitz S (2001) Does amoeboid reasoning explain the evolution and maintenance of virulence factors in Cryptococcus neoformans? Proc Natl Acad Sci U S A 98:14760–14762PubMedCrossRefGoogle Scholar
  37. Long M, Huang S, Wu C, Shackleford G, Jong A (2012) Lipid raft/caveolae signaling is required for Cryptococcus neoformans invasion into human brain microvascular endothelial cells. J Biomed Sci 19(1):19PubMedCrossRefGoogle Scholar
  38. Lortholary O, Poizat G, Zeller V, Neuville S, Boibieux A, Alvarez M, Dellamonica P, Botterel F, Dromer F, Chene G (2006) Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 20(17):2183–2191PubMedCrossRefGoogle Scholar
  39. Luberto C, Martinez-Marino B, Taraskiewicz D, Bolanos B, Chitano P, Toffaletti D, Cox G, Perfect J, Hannun Y, Balish E, Del Poeta M (2003) Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans. J Clin Invest 112:1080–1094PubMedGoogle Scholar
  40. MacNeill A, Moldawer L, Moyer R (2009) The role of the cowpox virus crmA gene during intratracheal and intradermal infection of C57BL/6 mice. Virology 384(1):151–160PubMedCrossRefGoogle Scholar
  41. Mansour M, Vyas J, Levitz S (2011) Dynamic virulence: real-time assessment of intracellular pathogenesis links Cryptococcus neoformans phenotype with clinical outcome. MBio 2(5). pii: e00217-11Google Scholar
  42. Mirkov I, Stojanovic I, Stosic-Grujicic S, Glamoclija J, Zolotarevski L, Kataranovski D, Kataranovski M (2010) Splenic and lung response to nonlethal systemic Aspergillus fumigatus infection in C57BL/6 mice. Med Mycol 48(5):735–743PubMedCrossRefGoogle Scholar
  43. Moyrand F, Janbon G (2004) UGD1, encoding the Cryptococcus neoformans UDP-glucose dehydrogenase, is essential for growth at 37 °C and for capsule biosynthesis. Eukaryot Cell 3(6):1601–1608PubMedCrossRefGoogle Scholar
  44. Nielsen K, Cox GM, Litvintseva AP, Mylonakis E, Malliaris SD, Benjamin DK Jr, Giles SS, Mitchell TG, Casadevall A, Perfect JR, Heitman J (2005) Cryptococcus neoformans alpha strains preferentially disseminate to the central nervous system during coinfection. Infect Immun 73(8):4922–4933PubMedCrossRefGoogle Scholar
  45. Park B, Wannemuehler KA, Marston BJ, Govender N, Pappas P, Chiller T (2009) Estimation of the global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23:525–530PubMedCrossRefGoogle Scholar
  46. Patten C Jr, Myles M, Franklin C, Livingston R (2010) Perturbations in cytokine gene expression after inoculation of C57BL/6 mice with Pasteurella pneumotropica. Comp Med 60:18–24PubMedGoogle Scholar
  47. Perfect J, Dismukes W, Dromer F, Goldman D, Graybill J, Hamill R, Harrison T, Larsen R, Lortholary O, Nguyen M, Pappas P, Powderly W, Singh N, Sobel J, Sorrell T (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 50(3):291–322PubMedCrossRefGoogle Scholar
  48. Perfect J, Lang S, Durack D (1980) Chronic cryptococcal meningitis: a new experimental model in rabbits. Am J Pathol 101:177–194PubMedGoogle Scholar
  49. Rivera J, Feldmesser M, Cammer M, Casadevall A (1998) Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection. Infect Immun 66:5027–5030PubMedGoogle Scholar
  50. St Leger A, Peters B, Sidney J, Sette A, Hendricks R (2011) Defining the herpes simplex virus-specific CD8+ T cell repertoire in C57BL/6 mice. J Immunol 186:3927–3933PubMedCrossRefGoogle Scholar
  51. Toffaletti D, Rude T, Johnston S, Durack D, Perfect J (1993) Gene transfer in Cryptococcus neoformans by use of biolistic delivery of DNA. J Bacteriol 175(5):1405–1411PubMedGoogle Scholar
  52. Vidotto V, Sinicco A, Di Fraia D, Cardaropoli S, Aoki S, Ito-Kuwa S (1997) Phospholipase activity in Cryptococcus neoformans. Mycopathologia 136(3):119–123CrossRefGoogle Scholar
  53. Wozniak K, Ravi S, Macias S, Young M, Olszewski M, Steele C, Wornley F (2009) Insights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosis. PLoS One 4(9):e6854PubMedCrossRefGoogle Scholar
  54. Yoneda A, Doering T (2008) Regulation of Cryptococcus neoformans capsule size is mediated at the polymer level. Eukaryot Cell 7(3):546–549PubMedCrossRefGoogle Scholar
  55. Zaragoza O, Rodrigues M, De Jesus M, Frases S, Dadachova E, Casadevall A (2009) The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol 68:133–216PubMedCrossRefGoogle Scholar
  56. Zaragoza O, Alvarez M, Telzak A, Rivera J, Casadevall A (2007) The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response. Infect Immun 75(6):2729–2739PubMedCrossRefGoogle Scholar
  57. Zaragoza O, Casadevall A (2004) Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online 6(1):10–15PubMedCrossRefGoogle Scholar
  58. Zaragoza O, Telzak A, Bryan R, Dadachova E, Casadevall A (2006) The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding. Mol Microbiol 59(1):67–83PubMedCrossRefGoogle Scholar
  59. Zhang Y, Wang F, Tompkins K, McNamara A, Jain A, Moore B, Toews G, Huffnagle G, Olszewski M (2009) Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination in highly virulent Cryptococcus neoformans H99. Am J Pathol 175(6):2489–2500PubMedCrossRefGoogle Scholar

Copyright information

© Journal of NeuroVirology, Inc. 2013

Authors and Affiliations

  • A. Pool
    • 1
    • 2
  • L. Lowder
    • 2
  • Y. Wu
    • 1
    • 2
  • K. Forrester
    • 1
  • J. Rumbaugh
    • 1
    • 2
    • 3
  1. 1.Department of NeurologyEmory University School of MedicineAtlantaUSA
  2. 2.Division of NeurologyAtlanta Veterans Administration Medical CenterAtlantaUSA
  3. 3.DecaturUSA

Personalised recommendations